Blood-brain barrier disruption chemotherapy

Handbook of Brain Tumor Chemotherapy

Volumn , Issue , 2006, Pages 262-273

  Doolittle, Nancy D ^a   Murillo, Tulio P ^b   Neuwelt, Edward A ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 38749105194     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088410-0/50056-1     Document Type: Chapter

References (48)

1. Groothuis D.R., Vriesendorp F.J., Kupfer B., et al. Quantitative measurements of capillary transport in human brain tumors by computed tomography. Ann Neurol 1991, 30:581-588.
2. Levin V.A., Clancy T.P., Ausman J.I., Rall D.P. Uptake and distribution of 3H-methotrexate by the murine ependymoblastoma. J Natl Cancer Inst 1972, 48:875-883.
3. Groothuis D.R. The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro-oncol 2000, 2:45-59.
4. Neuwelt E.A. Mechanisms of disease: the blood-brain barrier. Neurosurgery 2004, 54:131-142.
5. Neuwelt E.A., Barnett P.A., Hellstrom K.E., et al. Delivery of melanoma-associated specific immunoglobulin monoclonal antibody and Fab fragments to normal brain utilizing osmotic blood-brain barrier disruption. Cancer Res 1988, 48:4725-4729.
6. Neuwelt E.A., Frenkel E.P., Rapoport S., Barnett P. Effect of osmotic blood-brain barrier disruption on methotrexate pharmacokinetics in the dog. Neurosurgery 1980, 7:36-43.
7. vol 2. Implications of the Blood-Brain Barrier and Its Manipulation 1989, Plenum Publishing Corporation, New York. E.A. Neuwelt (Ed.).
8. Kroll R.A., Neuwelt E.A. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 1998, 42:1083-1100.
9. Remson L.G., McCormick C.I., Sexton G., Pearse H.D., Garcia R., Neuwelt E.A. Decreased delivery and acute toxicity of cranial irradiation and chemotherapy given with osmotic blood-brain barrier disruption in a rodent model: the issue of sequence. Clin Can Res 1995, 1:731-739.
10. Remsen L.G., Marquez C., Garcia R., Thrun L.A., Neuwelt E.A. Efficacy after sequencing of brain radiotherapy and enhanced antibody targeted chemotherapy delivery in a rodent human lung cancer brain xenograft model. Int J Radiat Oncol Biol Phys 2001, 51:1045-1049.
11. Remsen L.G., McCormick C.I., Sexton G., et al. Long-term toxicity and neuropathology associated with the sequencing of cranial irradiation and enhanced chemotherapy delivery. Neurosurgery 1997, 40:1034-1042.
12. Dahlborg S.A., Henner W.D., Crossen J.R., et al. Non-AIDS primary cns lymphoma: first example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy. The Cancer Journal from Scientific American 1996, 2:166-174.
13. Neuwelt E.A., Pagel M., Barnett P., Glasberg M., Frenkel E.P. Pharmacology and toxicity of intracarotid adriamycin administration following osmotic blood-brain barrier modification. Cancer Res 1981, 41:4466-4470.
14. Neuwelt E.A., Barnett P.A., Glasberg M., Frenkel E.P. Pharmacology and neurotoxicity of cis-Diamminedichloroplatinum, bleomycin, 5-fluorouracil, and cyclophosphamide administration following osmotic blood-brain barrier modification. Cancer Res 1983, 43:5278-5285.
15. Fortin D., McCormick C.I., Remsen L.G., Nixon R., Neuwelt E.A. Unexpected neurotoxicity of etoposide phosphate administered in combination with other chemotherapeutic agents after blood-brain barrier modification to enhance delivery, using propofol for general anesthesia, in a rat model. Neurosurgery 2000, 47:199-207.
16. Dahlborg S.A., Petrillo A., Crossen J.R., et al. The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery. The Cancer Journal from Scientific American 1998, 4:110-124.
17. McAllister L.D., Doolittle N.D., Guastadisegni P.E., et al. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 2000, 46:51-61.
18. Doolittle N.D., Miner M.E., Hall W.A., et al. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 2000, 88:637-647.
19. Tyson R.M., Siegal T., Doolittle N.D., Neuwelt E.A. Current status and future of relapsed primary central nervous system lymphoma (PCNSL). Leuk Lymphoma 2003, 44:627-633.
20. Doolittle N.D., Petrillo A., Bell S., Cummings P., Eriksen S. Blood-brain barrier disruption for the treatment of malignant brain tumors: the national program. J Neurosci Nurs 1998, 30:81-90.
21. Roman-Goldstein S., Clunie D.A., Stevens J., et al. Osmotic blood-brain barrier disruption: CT and radionuclide imaging. AJNR Am J Neuroradiol 1994, 15:581-590.
22. Fortin D., McAllister L.D., Nesbit G., et al. Unusual cervical spinal cord toxicity associated with intra-arterial carboplatin, intra-arterial or intravenous etoposide phosphate, and intravenous cyclophosphamide in conjunction with osmotic blood-brain barrier disruption in the vertebral artery. AJNR Am J Neuroradiol 1999, 20:1794-1802.
23. Williams P.C., Henner D.W., Roman-Goldstein S., et al. Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain barrier in the treatment of intracranial neoplasms. Neurosurgery 1995, 37:17-28.
24. Neuwelt E.A., Brummett R.E., Doolittle N.D., et al. First evidence of otoprotection against carboplatin-induced hearing loss with a two-compartment system in patients with central nervous system malignancy using sodium thiosulfate. J Pharmacol Exp Ther 1998, 286:77-84.
25. Doolittle N.D., Muldoon L.L., Brummett R.E., et al. Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Clin Cancer Res 2001, 7:493-500.
26. Doolittle N.D., Anderson C.P., Bleyer W.A., et al. Importance of dose intensity in neuro-oncology clinical trials: summary report of the sixth annual meeting of the Blood-Brain Barrier Disruption Consortium. Neuro-Oncology 2001, 3:46-54. for the Blood-Brain Barrier Disruption Consortium, (Posted to Neuro-Oncology, Doc. 00-039, November 3, 2000 neuro-oncology.mc.duke.edu.
27. Doolittle N.D., Abrey L.E., Ferrari N., et al. Targeted delivery in primary and metastatic brain tumors: summary report of the seventh annual meeting of the Blood-Brain Barrier Disruption Consortium. Clin Cancer Res 2002, 8:1702-1709.
28. Doolittle N.D., Abrey L.E., Bleyer W.A., et al. New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual Blood-Brain Barrier Disruption Consortium meeting. Clin Cancer Res 2005, 11:421-428.
29. Abrey L.E., DeAngelis L.M., Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 1998, 16:859-863.
30. Kraemer D.F., Fortin D., Doolittle N.D., Neuwelt E.A. Association of total dose intensity of chemotherapy in primary central nervous system lymphoma (human non-acquired immunodeficiency syndrome) and survival. Neurosurgery 2001, 48:1033-1041.
31. Neuwelt E.A., Guastadisegni P.E., Varallyay P., Doolittle N.D. Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery. AJNR Am J Neuroradiol 2005, 26:258-265. In press.
32. Alas S., Ng C.P., Bonavida B. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkins lymphoma. Clin Cancer Res 2002, 8:836-845.
33. Smith J.R., Rosenbaum J.T., Wilson D.J., et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 2002, 109:1709-1716.
34. Dedon P.C., Borch R.F. Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles. Biochem Pharmacol 1987, 36:1955-1964.
35. Elferink F., van der Vijgh W.J.F., Klein I., Pinedo H.M. Interaction of cisplatin and carboplatin with sodium thiosulfate: reaction rates and protein binding. Clin Chem 1986, 32:641-645.
36. Muldoon L.L., Pagel M.A., Kroll R.A., et al. Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity. Clin Cancer Res 2000, 6:309-315.
37. Muldoon L.L., Walker-Rosenfeld S.L., Hale C., Purcell S.E., Bennett L.C., Neuwelt E.A. Rescue from enhanced alkylator-induced cell death with low molecular weight sulfur-containing chemoprotectants. J Pharmacol Exp Ther 2001, 296:797-805.
38. Neuwelt E.A., Brummett R.E., Remsen L.G., et al. In vitro and animal studies of sodium thiosulfate as a potential chemoprotectant against carboplatin-induced ototoxicity. Cancer Res 1996, 56:706-709.
39. Neuwelt E.A., Pagel M.A., Hasler B.P., Deloughery T.G., Muldoon L.L. Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model. Cancer Res 2001, 61:7868-7874.
40. Neuwelt E.A., Pagel M.A., Kraemer D.F., Peterson D.R., Muldoon L.L. Bone marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain tumor model. J Pharmacol Exp Ther 2004, 309:594-599.
41. Dickey D.T., Muldoon L.L., Kraemer D.F., Neuwelt E.A. Protection against cisplatin-induced ototoxicity by N-acetylcysteine in a rat model. Hear Res 2004, 193:25-30.
42. Doolittle N.D., Tyson R.M., Lacy C., et al. Potential role of delayed sodium thiosulfate as protectant against severe carboplatin-induced thrombocytopenia in patients with malignant brain tumors. Blood 2001, 98(11):37a-38a. Abstract 149.
43. Doherty J.K., Bond C., Jardim A., Adelman J.P., Clinton G.M. The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor. Proc Natl Acad Sci U S A 1999, 96:10869-10874.
44. Staverosky J.A., Muldoon L.L., Guo S., Evans A.J., Neuwelt E.A., Clinton G.M. Herstatin, an autoinhibitor of the EGF receptor family, blocks the intracranial growth of glioblastoma. Clin Cancer Res 2005, 11:335-340.
45. Trail P.A., Willner D., Lasch S.J., et al. Antigen-specific activity of carcinoma-reactive BR64 doxorubicin conjugates evaluated in vitro and in human tumor xenograft models. Cancer Res 1992, 52:5693-5700.
46. Muldoon L.L., Neuwelt E.A. BR96-DOX immunoconjugate targeting of chemotherapy in brain tumor models. J Neurooncol 2003, 65:49-62.
47. Varallyay P., Nesbit G., Muldoon L.L., et al. Comparison of two super paramagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors. AJNR Am J Neuroradiol 2002, 23:510-519.
48. Neuwelt E.A., Varallyay P., Bago A., Muldoon L.L., Nesbit G., Nixon R. Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumours. Neuropathol Appl Neurobiol 2004, 30(5):456-471.